Fast Locator 2011-2012: Dr. Reddy's Laboratories Inc. - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Dr. Reddy's Laboratories Inc.

The need to access emerging markets with new, cost-effective drugs, the reduction of NCEs that have been introduced to the market, the diminishing Blockbuster product model, and the far more complicated Life Cycle Management programs are just some of the new and ever-changing challenges that innovative pharmaceutical companies face in today's environment.

This is amplified by the increasing cost pressures from Healthcare payers for both governments and health care providers alike.

However, what has remained unchanged in the industry is the need to deliver high-quality, efficacious, and cost-effective medicine to patients while delivering high-value returns to the investors.

Even the emerging markets are demanding access to new and effective treatments at the same time as the rest if the established markets, but at a price which makes the products affordable to them.

CPS is able to help these innovator companies by offering innovative solutions through cost-effective development and manufacturing as well as with cutting edge science. It is by delivering solutions to the problems that the innovators encounter where CPS brings value.

Because of Dr. Reddy's experience in delivering high-quality, cost-effective medicines across the globe, CPS has the proven skill set to help the innovator forge their way through these new and serious challenges. We believe that only through intensified collaborations, we are able to address these external forces.


Regions where services are provided:

Asia, North America, Europe, Latin America.

Outsourcing services provided:

Development and Phase I/II CTM

  • Biocatalysis
  • Borane chemistry
  • Bromine chemistry/bromination
  • Carbohydrate chemistry
  • Cryogenics (lower-temperature reactions)
  • Chemocatalysis
  • Drug delivery
  • Injectible products development
  • Solid dose development
  • Process development-small molecule

Commercial Manufacturing

  • API and advanced intermediates (CGMP, small molecules)
  • Cyanide chemistry
  • Fluorination
  • Heterocyclic chemistry
  • High-potency or high-containment manufacturing
  • Injectables
  • Solid dosage forms

Analytical Services

  • Chemistry and stability
  • Hydrazine chemistry
  • Lithium chemistry
  • Microbiology
  • Nitration
  • Organometallic chemistry
  • Particle characterization

API Production Technologies

  • Acetylenic chemistry
  • Acid Chlorides
  • Acylation Prostaglandins
  • Amidation
  • Amino acids and analogs
  • Asymmetric synthesis or chiral chemistry
  • Azide chemistry
  • PEGs
  • Phosgenation
  • Steroids
  • Sulfonation



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here